CSBIO(SZ:300255)2025-09-15 10:18Group 1: Company Vision and Development Goals - The company aims to deepen its heparin business and promote the export of heparin preparations and raw materials, while actively responding to domestic market changes to achieve recovery and growth in heparin sales [2][3] - The company is transitioning towards becoming an innovative drug enterprise, with a focus on innovative drugs as a key development direction [2][3] Group 2: Product Development and Approval Process - The submission of supplementary materials for Abena peptide is a complex technical task that requires significant effort, and the company is striving to complete it as soon as possible [3][4] - The approval process for Abena peptide involves multiple stages, and the company cannot guarantee that submission of supplementary materials will lead to market approval [4][5] - The company has invested over 10 years in the research and development of Abena peptide, indicating a strong commitment to its successful market entry [3][4] Group 3: Market and Sales Strategy - The company has a production capacity of over 20 million units annually for Abena peptide, which is currently in the clinical trial phase [5][6] - The marketing team for Abena peptide is being established, with ongoing training and strategy development, although specific details cannot be disclosed at this time [6][7] - The company is currently focused on domestic clinical trials for Abena peptide and has not yet set specific market targets for expansion [5][6] Group 4: Investor Relations and Communication - The company emphasizes transparency and compliance in its communication with investors, ensuring that all significant developments will be disclosed according to regulatory requirements [6][7] - The company reassures investors that the renaming of Abena peptide does not impact its market approval process or investment value [5][6]